» Articles » PMID: 29350243

Current Opinions on Nephrolithiasis Associated with Primary Hyperparathyroidism

Overview
Journal Urolithiasis
Publisher Springer
Specialty Urology
Date 2018 Jan 20
PMID 29350243
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Nephrolithiasis is a common urological disease and could be secondary to primary hyperparathyroidism (PHPT). PHPT is traditionally characterised with hypercalcaemia. Recently, a normocalcemic PHPT has been officially recognised at the International Workshops. Regarding this new phenotype, nephrolithiasis is frequently found in studies that evaluate low bone mass. However, until now, no study on aetiology of nephrolithiasis considered normocalcemic PHPT. Hypercalciuria related to PHPT is considered as an important risk factor of stone formation in hypercalcemic PHPT, but the precise relationships between hypercalcemic PHPT and nephrolithiasis and between normocalcemic PHPT and nephrolithiasis remain unclear. In patients with hypercalcemic PHPT, after a surgical cure of PHPT, the renal calcium excretion and stone recurrence rate reduce but remain higher above health controls. This finding implies that abnormalities not caused by PHPT also probably affect stone formation. According to the new guideline, the presence of stones indicates the need for parathyroidectomy in patients with either hypercalcemic or normocalcemic PHPT unless contraindications exist. Patients with contraindications for parathyroidectomy or those who do not want to receive parathyroidectomy should be monitored for signs of disease progression and given of medical management. Moreover, due to decreased but significantly higher frequency of nephrolithiasis above those of healthy controls, patients with nephrolithiasis associated with PHPT after parathyroidectomy still should be motivated to explore strategies to prevent stone occurrence.

Citing Articles

An exploratory study evaluated the 30 most commonly reported medications in the United States food and drug administration's adverse event reporting system that are associated with the occurrence of kidney stones.

Bao E, Yang Y, Jiang B, Wang B, Liu Y, Yang L Front Pharmacol. 2025; 15:1377679.

PMID: 39764463 PMC: 11701592. DOI: 10.3389/fphar.2024.1377679.


The Multidisciplinary Approach in the Management of Patients with Kidney Stone Disease-A State-of-the-Art Review.

Balawender K, Luszczki E, Mazur A, Wyszynska J Nutrients. 2024; 16(12).

PMID: 38931286 PMC: 11206918. DOI: 10.3390/nu16121932.


Role of Nutrition in the Management of Patients with Multiple Endocrine Neoplasia Type 1.

Marinari M, Marini F, Giusti F, Brandi M Nutrients. 2024; 16(11).

PMID: 38892509 PMC: 11174418. DOI: 10.3390/nu16111576.


Delayed Diagnosis of Primary Hyperparathyroidism: A Case Report.

Silva M Cureus. 2023; 15(11):e49383.

PMID: 38146580 PMC: 10749559. DOI: 10.7759/cureus.49383.


Neuroendocrine Parathyroid Tumors: Quality of Life in Patients with Primary Hyperparathyroidism.

Carsote M, Nistor C, Stanciu M, Popa F, Cipaian R, Popa-Velea O Biomedicines. 2023; 11(7).

PMID: 37509698 PMC: 10377520. DOI: 10.3390/biomedicines11072059.


References
1.
LUMB G, STANBURY S . Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med. 1974; 56(6):833-9. DOI: 10.1016/0002-9343(74)90812-2. View

2.
Vezzoli G, Terranegra A, Soldati L . Calcium-sensing receptor gene polymorphisms in patients with calcium nephrolithiasis. Curr Opin Nephrol Hypertens. 2012; 21(4):355-61. DOI: 10.1097/MNH.0b013e3283542290. View

3.
Rejnmark L, Vestergaard P, Mosekilde L . Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab. 2011; 96(8):2377-85. DOI: 10.1210/jc.2011-0569. View

4.
Yang A, Hsu C, Chen J, Tseng L, Won G, Lee C . Normocalcemic primary hyperparathyroidism in patients with recurrent kidney stones: pathological analysis of parathyroid glands. Virchows Arch. 2006; 449(1):62-8. DOI: 10.1007/s00428-006-0222-5. View

5.
Silverberg S, Walker M, Bilezikian J . Asymptomatic primary hyperparathyroidism. J Clin Densitom. 2013; 16(1):14-21. PMC: 3987990. DOI: 10.1016/j.jocd.2012.11.005. View